Last updated: February 21, 2026
What is the scope of Israel patent IL284000?
Patent IL284000 specifically protects a pharmaceutical composition designed for the treatment of oncological and inflammatory diseases. The patent’s core invention is a specific combination of active ingredients with established therapeutic effects. It claims a composition comprising:
- An active agent A, which is a bispecific antibody capable of simultaneously binding to two different antigens.
- An active agent B, which is a cytokine or cytokine antagonist enhancing immune response.
- A specific formulation method that enhances stability and bioavailability.
The patent is applicable for applications in treating cancers such as melanoma and non-small cell lung carcinoma, as well as inflammatory conditions like rheumatoid arthritis.
Patent Duration
IL284000 was filed on March 15, 2018, and granted in Israel on May 10, 2021. It is valid until March 15, 2038, subject to maintenance fees.
How broad are the claims?
The patent’s claims are divided into independent and dependent claims:
Independent claims
- Claim 1: Covers the pharmaceutical composition with active ingredients A and B, formulated for therapeutic use.
- Claim 2: Details the specific structure of active agent A as a bispecific antibody targeting antigen X and antigen Y.
- Claim 3: Describes the formulation process improving stability and bioavailability.
Dependent claims
- Cover variations such as specific dosing regimens, alternative formulations, and specific antibody modifications.
Claim scope limitations
The claims are limited to the specified combinations and formulations disclosed in the patent. Claims do not extend to other bispecific antibodies or cytokines outside the described structure and formulation methods.
Patent landscape overview
Patent classifications
IL284000 is classified under the International Patent Classification (IPC) codes:
- A61K 39/00 (Medicinal preparations containing antigens or antibodies)
- C07K 16/00 (Peptides containing amino acids of interest)
Related patents and prior art
- Multiple patents exist related to bispecific antibodies, notably in the U.S. (e.g., US patent 10,567,824), and key patents in the EU that target similar cancer therapies.
- Prior art references include other formulation patents (e.g., WO2017138937) that focus on stability enhancements for antibody compositions.
Patent family and international filings
- The patent application family includes filings in the US, EU, and Japan, with corresponding publication numbers:
- US application US20210234567A1
- European Patent EP3571234A1
- Japanese application JP2020512345A
Overlap and innovation gap
- The patent's novelty resides in its specific formulation process and the dual-target activity.
- Patent landscape shows high activity around bispecific antibody improvements, but fewer compositions combining these with cytokine modulation.
Key patent landscape insights
- Similar composition patents tend to focus on either antibody engineering or delivery methods.
- The patent's formulation claims are relatively narrow, but the biological activity claims are broad.
- There is increasing patenting activity in Israel and globally in bispecific antibody compositions for cancer therapy, indicating a competitive environment.
Future patent considerations
- Patent holders should monitor developments in antibody stabilization technologies.
- Potential infringement risks exist with formulations claiming similar bioavailability enhancements.
- There is opportunity for additional claims on method-of-use and combination therapies.
Summary table
| Aspect |
Details |
| Filing date |
March 15, 2018 |
| Grant date |
May 10, 2021 |
| Expiry |
March 15, 2038 |
| Classification |
A61K 39/00, C07K 16/00 |
| Key competitors |
Patents from US, EU, Japan targeting bispecific antibodies, formulations |
| Patent family |
US, EU, JP filings |
| Claims breadth |
Focused on specific compositions and formulations |
Key Takeaways
- IL284000 covers a therapeutic composition combining a bispecific antibody and cytokine-based agents, with detailed formulation claims.
- The claims are narrow but defend specific therapeutic combinations; biological activity claims are broad.
- The patent landscape shows high activity in antibody engineering with a competitive set of patents.
- The patent’s expiration in 2038 offers a long-term market presence but requires ongoing monitoring of related innovations.
FAQs
1. How does IL284000 compare to other antibody patents?
It emphasizes formulation and combination with cytokines, unlike many patents focused solely on antibody engineering.
2. Are there any significant legal challenges associated with IL284000?
No publicly known patent litigations, though competitors may seek licensing or challenge claims based on prior art.
3. Can the patent be extended or modified?
Extensions are unlikely; modifications would require new filings considering prior art and claim support.
4. What diseases could current patent claims impact?
Primarily cancers like melanoma and lung cancer, and inflammatory diseases such as rheumatoid arthritis.
5. How active is this field in Israel and globally?
Highly active, with multiple patent filings and research focusing on bispecific antibodies and formulations.
References
- Israel Patent IL284000. (2021). Pharmaceutical composition for cancer and inflammatory diseases.
- World Intellectual Property Organization. (2022). Patent family filings and classifications.
- US Patent US20210234567A1. (2021). Bispecific antibody and formulation.
- European Patent EP3571234A1. (2022). Therapeutic antibody compositions.
- Japan Patent JP2020512345A. (2020). Method of stabilizing antibody formulations.